Compare ING Groep NV (ING) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs DENTSPLY SIRONA Inc — how do they compare? ING Groep NV trades at $33.36 (market cap $93.76B), while DENTSPLY SIRONA Inc trades at $8.82 (market cap $1.73B). The key difference: ING Groep NV is far larger — about 54.2× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 94 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| ING | XRAY | |
|---|---|---|
Market Cap | $93.76B | $1.73B |
Volume | 4,620,220 | 6,198,582 |
Sector | Financials | Health |
52-Week High | $37.27 | $14.68 |
52-Week Low | $23.66 | $8.52 |
Typical Hold Time | 94 Days | 72 Days |
Enterprise Value | $236.48B | $3.80B |
Dividend Yield | 3.95% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $33.37, down 1.62% on the day, with a bearish technical signal from moving averages and oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.79 exceeding the $0.75 estimate. Revenue for 2025 reached $22.90 billion, with a net income margin of 28.34%, though cash flow trends show persistent net outflows. Analyst consensus is bullish with 11 buy ratings and no sell recommendations.
The outlook for ING is supported by raised ROE targets and organic growth initiatives, but risks include negative cash flows and regulatory scrutiny. The stock offers value with a P/E of 12.86 and dividend yield, yet investors face headwinds from operational cash burn and macroeconomic sensitivity.
DENTSPLY SIRONA (XRAY) trades at $8.83, down 3.4% with bearish technical signals. The stock faces fundamental challenges with negative net income margins (-14.99%) and declining revenue trends ($3.68B in 2025). Recent Q2 2026 earnings beat expectations but sales fell 4.1% amid ongoing turnaround efforts. The company maintains strong institutional interest despite hitting 52-week lows in September 2026.
XRAY presents a high-risk opportunity with Wall Street maintaining a cautious stance (37.5% buy rating). The consensus price target of $13.40 offers 52% upside potential, but investors face execution risks in the dental equipment turnaround, margin pressures, and competitive challenges. Near-term catalysts include management's presentation at the Baird Healthcare Conference in September 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
